Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3145–3168 of 85,985 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Multiple Myeloma
Interventions: ASP7487, Velcade, Dexamethasone; Drug
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia • Chicago, Illinois

Conditions: Pediatric Post-tonsillectomy Pain
Interventions: Dexamethasone, Placebo; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 4 Years to 17 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Early Breast Cancer
Interventions: Giredestrant, Anastrozole, Palbociclib, Surgery; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Burbank, California • Laguna Hills, California • San Luis Obispo, California + 7 more

Conditions: Bipolar Depression
Interventions: Medtronic Percept RC System, One Month Blinded Discontinuation Period; Device · Behavioral
Lead sponsor: Wayne Goodman MD; Other
Eligibility: 22 Years to 64 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Boston, Massachusetts • Houston, Texas • Seattle, Washington

Conditions: Diabetes Mellitus
Interventions: Glucose to Goal, Usual Care; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4,994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions: lapatinib, paclitaxel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Osteoarthritis
Interventions: TDS-943 (topical diclofenac sodium 4% spray), celecoxib, placebo; Drug · Other
Lead sponsor: Mika Pharma GmbH; Industry
Eligibility: 40 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 49
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 42 more

Conditions: Growth Disorder, Growth Hormone Deficiency in Children
Interventions: No treatment given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 4 Years to 13 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 24
States / cities: Phoenix, Arizona • Centennial, Colorado • Wilmington, Delaware + 20 more

Conditions: Smoking, Withdrawal Nicotine, ADHD
Interventions: Cigarette smoking, Abstinence; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Santa Ana, California

Conditions: Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions: Prostatic artery embolization; Device
Lead sponsor: Andrew Picel; Other
Eligibility: 45 Years to 85 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Arthritis, Psoriatic, Arthritis, Rheumatoid
Interventions: Incentive; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg, Benicar HCT® Tablets 40 mg/25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Opioid Use, Postpartum Disorder, Chronic Pain Syndrome
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Lymphoma
Interventions: bortezomib, gemcitabine hydrochloride; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis (MS)
Interventions: Ocrelizumab, rHuPH20; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 18
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Alexandria, Louisiana + 15 more

Conditions: Pain, Chronic
Interventions: Intradural Spinal Cord Stimulation, Administration of Questionnaires; Device · Behavioral
Lead sponsor: Matthew Howard; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Alzheimer's Disease
Interventions: LY2811376, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Respiratory Papillomatosis
Interventions: INO-3107, CELLECTRA® 2000; Drug · Device
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 7 more

Conditions: PARKINSON DISEASE (Disorder), Parkinson s Disease
Interventions: TMS; Device
Lead sponsor: San Francisco Neurology and Sleep Center; Other
Eligibility: 50 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Melasma
Interventions: Fractional 1927nm Low-Powered Diode Laser, Topical Cysteamine; Device · Other
Lead sponsor: UnionDerm; Other
Eligibility: 18 Years to 74 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatic Impairment
Interventions: TR-701 FA; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Orlando, Florida • Minneapolis, Minnesota

Conditions: Open-angle Glaucoma
Interventions: Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Vehicle; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C
Interventions: GSK2485852 70 mg, GSK2485852 420 mg, placebo, GSK2485852 630 mg, GSK2485852 70 mg + Ritonavir 100mg, GSK2485852 210 mg +Ritonavir 100mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 5
States / cities: Anaheim, California • Orlando, Florida • Lenexa, Kansas + 2 more

Conditions: Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
Interventions: bifeprunox, Placebo; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 65 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 35
States / cities: Phoenix, Arizona • Carson, California • Long Beach, California + 28 more

Search by objective public record fields.

A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma

Dexamethasone and Post-tonsillectomy Pain in Children

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

Deep Brain Stimulation of Treatment-Resistant Bipolar Depression

Glucose to Goal: A Model to Support Diabetes Management in Primary Care

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial II

Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)

Association Between Smoking, Brain Activity, Genes, and ADHD

Prostatic Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)

Stepping Up For Inflammatory Arthritis

Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg

Prevention of Persistent Opioid Use in Mothers

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

Intradural Percutaneous Stimulation

A Safety Study of LY2811376 Single Doses in Healthy Subjects

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Effects of Accelerated rTMS On Motor and Cognitive Function in Parkinson's Disease

Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma

A PK and Safety Study in Subjects With Hepatic Impairment

Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects

Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type